DU80 Stock Overview
A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.69 |
| 52 Week High | AU$2.98 |
| 52 Week Low | AU$0.54 |
| Beta | 0.46 |
| 1 Month Change | 0% |
| 3 Month Change | -0.71% |
| 1 Year Change | -61.09% |
| 3 Year Change | -92.45% |
| 5 Year Change | n/a |
| Change since IPO | -96.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| DU80 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.0% |
| 1Y | -61.1% | -5.9% | 6.9% |
Return vs Industry: DU80 underperformed the German Life Sciences industry which returned -5.9% over the past year.
Return vs Market: DU80 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| DU80 volatility | |
|---|---|
| DU80 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DU80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine DU80's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 55 | Kevin Camilleri | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| DU80 fundamental statistics | |
|---|---|
| Market cap | €3.40m |
| Earnings (TTM) | -€7.20m |
| Revenue (TTM) | €5.80m |
0.6x
P/S Ratio-0.5x
P/E RatioIs DU80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DU80 income statement (TTM) | |
|---|---|
| Revenue | AU$9.67m |
| Cost of Revenue | AU$3.76m |
| Gross Profit | AU$5.91m |
| Other Expenses | AU$17.93m |
| Earnings | -AU$12.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 61.12% |
| Net Profit Margin | -124.24% |
| Debt/Equity Ratio | 35.2% |
How did DU80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:41 |
| End of Day Share Price | 2024/10/16 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marc Kennis | APP Securities Pty Ltd. |
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Chris Kallos | MST Financial Services Pty Limited |